Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CMS Sickle Cell Gene Therapy Access Model

16 Dec 2024

Abstract excerpt

This Viewpoint explores and provides policy recommendations for the Cell and Gene Therapy Access Model recently launched by the US Centers for Medicare & Medicaid Services (CMS), which aims to increase access to Medicaid recipiencts with rare and severe diseases.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39680389
DOI: 10.1001/jamapediatrics.2024.5536

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CMS Sickle Cell Gene Therapy Access ModelPMID 39680389Read ↗

Advances in Sickle Cell Disease Treatment: A Comparative Review of Hematopoietic Stem Cell Transplantation and Gene Therapy (Casgevy and Lyfgenia)Semantic proximity Read ↗

Improving access to gene therapy for rare diseasesSemantic proximity Read ↗

Gene therapy for sickle cell disease: where we are now?Semantic proximity Read ↗

Strengthening health systems for access to gene therapy in rare genetic disordersSemantic proximity Read ↗

Patient, consumer and societal values, perceptions and preferences on high-cost gene therapiesSemantic proximity Read ↗

A new frontier: FDA approvals for gene therapy in sickle cell diseaseSemantic proximity Read ↗

Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence.Semantic proximity Read ↗

The Next Phase of Human Gene-Therapy OversightSemantic proximity Read ↗

Estimating the Financial Impact of Gene Therapy*Semantic proximity Read ↗

Coverage of new genetic technologies: what matters to insurers?Semantic proximity Read ↗

Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicineSemantic proximity Read ↗

The estimated annual financial impact of gene therapy in the United StatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.